Expiring patents, declining prices, growing competition – the pharmaceutical industry is undergoing rapid changes. Innovative ideas are needed to transform risks into opportunities.

https://www.fiercebiotech.com/biotech/loxo-bayer-maintain-90-plus-response-rate-cancer-trial

Conference Series Ltd invites all the participants from all over the world to attend the “World Congress on Advanced Pharmacy and Clinical Research” during July 16-17, 2018 at Sydney, Australia which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Advanced Pharmacy 2018 mainly emphasizes on the topics like Innovations in Drug discovery & Development , Pharmacovigilance & Clinical Trials, Molecular and Cellular Biology, Biopharmaceuticals and biosimilars, Computational Chemistry & Molecular Drug Design, Pharmacogenomics , Biomarkers and New drug targets, Pharmacology & Toxicology , Clinical Pharmacy & Pharmacy Community, Advancement in bioanalysis, Industrial & Regulatory pharmacy, Nanotechnology in Drug Delivery, Medicinal research , Advances in pharma analytical methods, Entrepreneurs Investment Meet

The Chinese pharmaceutical firm plans to open a research centre in San Diego and acquire rights to distribute newly developed drugs in the US in China.
Shanghai Pharmaceuticals Holding, one of China’s largest pharmaceutical firms, is scouting for acquisitions in the United States and Europe, despite increased scrutiny of Chinese investments.Acquisitions, including overseas ones, is one of the firm’s two-pronged development strategy besides in-house research and development, according to chairman of Zhou Jun.
“We are deploying more people and financial resources to do our own research and development, and are also seeking to gain technology and market access through the short-cut route of acquisitions,” he told the South China Morning Post in an interview on the sidelines of the JP Morgan Healthcare Conference in San Francisco earlier this month.
The Hong Kong and Shanghai-listed firm has spent US$100 million to US$150 million annually on R&D, amounting to 15 to 20 per cent of its profit in recent years.
Read More: http://bit.ly/ShanghaiPharma

How best to align market access and R&D? We know, it’s been a question of discussion for years now, yet it remains a heated debate.

Should we be aiming for early, phased access? Should we continue to emphasise the focus of involving access departments early in the life cycle to maximise launch? How do we gain the benefits of maximising launch options without adding significant delays and development costs?

Sign-up for our latest webinar: https://goo.gl/Sb992z on Thursday 25th Jan, and kick of 2018 in the right way, as we bring together key industry leaders to discuss the best path forward for 2018 and beyond.

Expert panellists include:

• Pernille Storm, Global Market Access Director Neurology, Lundbeck
• Simon Shohet, Senior Director, Market Access and Pricing, Ipsen
• Michael Lees, Head of Value, Evidence & Portfolio Strategy (EUCAN), Takeda

Click here to sign-up: https://goo.gl/Sb992z

And also remember, all sign-ups receive the recordings so don’t worry if you can’t make the timings.

Necessity is the mother of invention. That’s why generics companies are out-innovating the rest of the industry, developing marketing tactics on tiny budgets that still engage the customer.

We’ve prepared a new webinar on 18th January on “Lean Marketing Innovation for Generics” https://goo.gl/EXPVi3, delivered by leading marketers at generics manufacturers including:

- Anne Baille, Vice President Strategic Marketing, International Women’s Health, Allergan
- Petr Kozel, Vice President Sales and Marketing, Actavis
- Ursula Scheideler, Director Marketing Gx, Teva
….where they explain how they manage to communicate value to their customers.

Today’s war is being fought on the Customer Experience battlefield. Savvy generics marketers are showing that it can be achieved - it’s not about the size of your budget – it’s about what you do with it.

You won’t want to miss this one. Sign up for free here https://goo.gl/EXPVi3

Also, don’t worry if you can’t make it on the day. We’ll send you access to the webinar recordings. But you still have to register! So– sign up here: https://goo.gl/EXPVi3

“Disruptive” technologies are transforming every aspect of healthcare – patients seek information differently, doctors diagnose and treat differently, and payers assess costs differently.

Dealing with these stakeholders every day, how will sales and marketing adapt to these changes and continue to add value?

In eyeforpharma’s latest report ‘Trends in Digital Innovation: https://goo.gl/2Se7rW we find out how pharma can continue to engage, whilst capitalizing on new “disruptive” technologies:

• Hear from BMS on how Artificial Intelligence helped them revolutionize customer engagement
• Learn from Microsoft on how smarter data and analytic techniques can help you can tap into the rhythms of patients’ lives to “treat the patient journey, not just the stops along the way”.
• Discover how Sanofi transformed its operating model “industrializing digital”

Access your free copy of the report here: https://goo.gl/2Se7rW

For any questions please contact Giselle Quartin gquartin@eyeforpharma.com

Data now drives our decisions. Or at least, we say it does. But how far has real world and customer data actually permeated our companies, and how many critical decisions are truly informed by it?

With so much time and money being invested in the sourcing, analysis and communication of your findings, you need to prove that the investment is worth it and that you’re investing in the right places.

To tackle these concerns, this new eyeforpharma whitepaper - https://goo.gl/svAEsX -,
Novartis, Janssen, Lilly and many more, discuss:

• The uses and advantages of real world data (RWD) use across R&D, access and commercial departments
• How the availability of new knowledge is transforming processes and organisational setup across the organisation
• How we interact with different customer types

Download your copy of the white paper here - https://goo.gl/svAEsX

Drug development requires urgent medical attention!

Tune in to eyeforpharma’s latest webinar with expert panellists; Paul Rowe (VP, Sanofi), Xavier Frapaise (formerly VP, Merck Serono) and Michael Zaiac (VP, Celgene), as they discuss the emerging role of Medical Affairs in the early stages of development.

Join us on November 29, 9am EST, 2pm UK, 3pm Europe, by signing-up here: https://goo.gl/DVxfuc

Key insights will include:

• Overcome internal cultural barriers to increase acceptance of medical’s value and ownership in early phases I and II
• Enhance medical evidence generation by bringing payer and market access team insights into early lifecycle management
• Be the voice of the patient from day 1 to ensure patient needs are met throughout development

Sign-up for free here – https://goo.gl/DVxfuc

And remember, if you can’t make the time, sign up anyway and we will send you the full recordings after the webinar.

Those who succeed in market access today - are those seizing the initiative and finding creative ways to work with the external environment. They are also re-shaping their internal structure to produce the best therapy narrative.

What does this all mean? Internally it’s about moving from a concept of research and development to value based development. Externally it is everything to do with identifying stakeholder’s priorities and motivations to achieve the best possible outcomes for market access strategies.

With valuable insights from Lundbeck, Astellas, Janssen and Takeda, download our free feature magazine today, as we discuss:

• The growing importance of market access in creating a commercial value proposition
• The evolving pharma- payer relationship
• How pharma can position as best in class partners to support payers battling with affordability

Access your copy here: https://goo.gl/Hi7e2j

Spoiler alert: They don’t. In our ever-more patient-centric world, we asked, “what do patients think of DTC promotion?”

eyeforpharma’s DTC whitepaper explores this and how Takeda, Astellas, and AstraZeneca are integrating patient involvement in advertising campaigns and increasing engagement. Download the paper here: https://goo.gl/j34qPx

You will get insights into:

• Exclusive results from the “DTC Attitudes, Behaviours and Preferences” study which shows exactly what patients think of DTC promotion.
• How listening to patient needs and involving them in the design of advertising is winning champions and delivering results
• The Future of DTC: Digital drives traffic and offers patient-centricity

Access your free copy today by clicking here: https://goo.gl/j34qPx

I’m really excited about this content, so please do let me know if you have any feedback.

Best regards,

Caitlin Champion

eyeforpharma I caitlin@eyeforpharma.com

Pharma continues to demonstrate real innovations in efforts to support patients and further healthcare, but admittedly more can be done despite restrictions to the way engage and communicate.
But all this is about the change in Barcelona next year.
eyeforpharma Barcelona 2018 (March 13-15), the world’s largest commercial pharma meeting of 1300+ visionary leaders from across the globe, will bring together market leaders and pioneers to share case studies, tangible takeaways that helps the business, customers and patients.
Click here to see who and what Barcelona 2018 will bring you: https://goo.gl/rFWr2M

2018 will guarantee:

• Be the solution you want to see: Create a holistic package which delivers outcomes and creates real value for patients
• You, the trusted source: Become your customer’s immediate go-to for authentic knowledge, reinventing your relationships
• Next-gen experience: See how a new digital culture uses tech and data to transform your engagement and communication plan
• Beyond partnerships: Align with key stakeholders at the world’s largest meeting for commercial pharma

Download your copy of the brochure here: https://goo.gl/rFWr2M

Exclusively for our group members we have secured a €200 discount on your attendance. Simply register and use the code “PharmeMed200” when prompted.

For any questions, or group enquires email Giselle on gquartin@eyeforpharma.com

With customer demands rising and face-to-face time diminishing, virtual engagement is one of the most promising ways to reach doctors and provide information. However, many pharma companies lack the expertise or capabilities to get their virtual strategy of the ground…

To explain how, we’ve teamed up with Lisa Huse (General Manager - Iberia, Roche), Hannelore Grams (Head of Digital Strategy EUCAN, Takeda), Panos Papakonstantinou (Head of Digital Commercial, Europe, Novartis) and Agnitio. In a free 1 hour webinar (Wednesday 15th November, 2PM GMT/3PM CET) in which we’ll explain how to effectively use virtual tech as part of your MCM strategy.

Click here to sign-up to the webinar for free: https://goo.gl/jXTTNf

You’ll find out:

• Why virtual engagement may be the smartest inclusion to your marketing mix

• The personalisation possibility: how smarter digital enables you to tailor your engagement with the individual customer

• How to integrate new engagement paradigms into your existing multichannel strategy and organisational setup

• The return of ROI: how to use well-understood metrics to demonstrate the success of technologies

Don’t miss out on this great discussion – sign up today: https://goo.gl/jXTTNf

And remember, if you can’t make the dates we will send you the full recordings so make sure you sign up anyway.

If you have any questions email Giselle Quartin: gquartin@eyeforpharma.com

Disruptive technologies are transforming every aspect of healthcare – doctors diagnose differently, regulators assess differently and pharma develops drugs differently.

How does a role increasingly demanded across this whole system adapt to these changes and continue to thrive?

In this latest Medical Affairs paper understand how medical must champion real-world evidence, artificial intelligence, digital health and adapt to a changing healthcare environment – to reach its full value potential. Find it here: https://goo.gl/VqEkXm

Some of the contributors to this 13-page paper include:

• Shontelle Dodson, SVP, Medical Affairs, Americas, Astellas
• Gundula Scheindewind, VP, Medical Affairs EU & Canada, Takeda
• Bozidar Jovicevic, VP, Global Head Digital Medicines, Sanofi
• Stanislav Glezer, CMO, Adocia
• Lav Parvathenani, Director of Publications and Scientific Content, BMS
• Iain Buchan, Director of Healthcare Research, Microsoft

You can get your free copy of the full paper here: https://goo.gl/VqEkXm

How many people 20 years ago do you think would have believed you if you told them Medical Affairs is the future of pharma?

Such has been the growth of Medical’s stature over recent years, the function has grown from a supplementary to playing a vital role in pharma’s strategic plans, ambition and vision.

To stay ahead of this ever-increasing list of both external and internal demands and responsibilities, a new Medical operating model is a must – with each company’s approach their own.

In this 15-page white paper, you will gain insights from:
- Gavin Corcoran, CMO, Allergan
- Azmi Nabulsi, Dep. CMSO and Head, Strategic and Professional Affairs, Takeda
- Niko Andre, Head of Global Medical Affairs, Roche
- Kirk Shephard, SVP, Global Medical Affairs Oncology, Eisai
- Dr Sotirios Stergiopoulos, SVP Global Medical Affairs, Ipsen
- And many more medical affairs leaders…

You can get a free copy of the paper here: https://goo.gl/awFkyM

How many people 20 years ago do you think would have believed you if you told them Medical Affairs is the future of pharma?

Such has been the growth of Medical’s stature over recent years, the function has grown from a supplementary to playing a vital role in pharma’s strategic plans, ambition and vision.

To stay ahead of this ever-increasing list of both external and internal demands and responsibilities, a new Medical operating model is a must – with each company’s approach their own.

In this 15-page white paper, you will gain insights from:
- Gavin Corcoran, CMO, Allergan
- Azmi Nabulsi, Dep. CMSO and Head, Strategic and Professional Affairs, Takeda
- Niko Andre, Head of Global Medical Affairs, Roche
- Kirk Shephard, SVP, Global Medical Affairs Oncology, Eisai
- Dr Sotirios Stergiopoulos, SVP Global Medical Affairs, Ipsen
- And many more medical affairs leaders…

You can get a free copy of the paper here: https://goo.gl/gUFzsU

As pharma’s customer landscape becomes more complex, our perception of value has changed. Just you wouldn’t be caught dead wearing those flares that were once your most prized possession, it’s no longer enough to focus only on the medicine.

What worked ten years ago does simply not feel right anymore and, increasingly, our customers require more comprehensive solutions.

So what are the disease-specific, technically-specific or customer-specific competencies that will create a new set of assets? How will the medicines we develop require new ways of operating and interacting with our customer?

During the hour, we’ll be looking at how companies are building new competencies and assets in non-drug areas, whether we can rely on our collective pipelines for our long-term prosperity, what new partnerships and competencies need to be built for improved personalisation in our medicines, and whether the international community is able and willing to reward pharma for this type of innovation.

We will leave the session having a better idea of where we should be placing our resources and energy over the next few years.

Please join us at https://goo.gl/toq9S8 .

And don’t worry if you’re busy on October 3rd – by registering, you’ll receive a recording of the session!

Most of us are working hard to develop stronger relationships and better insights from patients.

However, most of our efforts could best be described as ‘experimental’, without a real understanding of what really works and where we should place our limited resources.

On September 20th (1:30pm ET), we are hosting a free webinar which will help solve this. The aim is to show you how to keep track of the most important patient data with advanced analytics. Specifically, our speakers (from Deloitte and Cardinal Health) will take us through how to:

- Demonstrate the role our products play in improving outcomes, by using smarter analytics
- Understand the importance and utility of compliance, adherence and patient outcomes metrics for all therapies
- Work more closely with HCPs when keeping track of this important patient data using cloud-based platforms

This free webinar is vital for anyone who is looking to leverage patients and/or their data to widen market access, communicate with customers or prepare a launch campaign.

Sign up for the webinar here: https://goo.gl/6gFuqQ

Don’t worry if you can’t make it live – sign up anyway and I’ll send you the recording afterwards.

In the age of consumerism and so much customer choice, it’s essential you create loyalty and an experience that offers value to the customer. We can achieve this by adopting a customer experience approach that focus on the way we are engaging and interacting with our customer.

In our upcoming webinar, September 12th (2 pm GMT/ 3 pm CET), we will be joined by Philippe Kirby, Director Customer Engagement Capabilities, MSD, Rebecca Joslin, Head of Customer Experience Strategy, Shire and Steve Mason, Multichannel & Marketing Cloud Expert, Salesforce. Sign up here: https://goo.gl/niqjiT

This 1 hour free webinar will discuss:
• Ensure a synchronized strategy at every touch point to create the optimum customer journey
• Align the way in which you treat your customer across all areas of your organization in order to provide the most seamless experience possible
• Blend all your channels in ensure you are speaking to your customer in one harmonious voice

Sign-up here, even if you can’t make it live and we’ll be sure to send you the recordings: https://goo.gl/niqjiT

As we move into the digital era of medicine, real-life data has become of ever-growing importance in value demonstration.In eyeforpharma’s latest webinar, an expert panel including; Lisa Egbuonu-Davis, VP, Sanofi, Kristine Mullen, Former VP, Humana and Advisor to Evidation Health, and Andy Gunn, Global Head, UCB will explore the subject – sign-up here: https://goo.gl/2nC43U Panellists will show you how to: • Create a more effective digital evidence generation strategy by defining value upfront with payers and other key stakeholders• Capture novel patient insights that fill the gaps in patient journey understanding, optimizing value creation• Establish continued collection of real-life data to justify continued reimbursement at future evaluations• Generate the right evidence to enhance your value propositions with a greater understanding of payer needs and requirementsFollow this link for further details: https://goo.gl/2nC43U And, if you can’t make the dates don’t worry, the recordings will be sent to all sign-ups.

In this white paper, Patricia Santos-Serrao, RAC, MasterControl's director of clinical and regulatory solutions for pharmaceutical, blood, and biologics, discusses the five trends that will likely have the biggest impact on the pharmaceutical industry this year. http://bit.ly/PharmaTrends2017 Santos-Serrao is a member of the Regulatory Affairs Professional Society (RAPS) and the Drug Information Association (DIA) and has nearly two decades of experience in the regulatory affairs and clinical areas of the pharmaceutical industry. Following her exploration of the five biggest pharma trends of 2017, she explains how an Enterprise Quality Management Software (EQMS) solution can help companies meet the challenges posed by each trend and allow them to thrive in a perpetually-changing pharmaceutical industry. Download Free here: http://bit.ly/PharmaTrends2017

Healthcare today requires a multi-stakeholder approach to adapt to pharma’s ever-more complex ecosystem, companies are struggling to stay afloat and prosper and must strive to understand these forces and how companies are adapting to meet these developing needs.In eyeforpharma latest magazine we address the importance of the new multi-stakeholder approach https://goo.gl/iIhRO2This edition of trends in marketing delves into:- Pharma’s new multi-stakeholder model- The essential role that collaboration both internal and external, plays in this new model- The powerful currents of disruptive technology, patient-centricity, complex multichannel approaches and the customer experience surging around them- The 7 Steps to Digital transformation in actionWith key insights from UCB, Fresenius Medical Care, Merck, Boehringer Ingelheim, Janssen and Novartis. Download your copy of Trends in Marketing here: https://goo.gl/iIhRO2

Real-world evidence (RWE) is no longer a toy for the privileged few. It’s insights into disease and patient understanding, existing treatments, value demonstration and safety are beginning to impact daily operations ranging from clinical trial design, through to post-launch activities.   This new RWE thought-piece will explore how regulators and payers are adapting and facilitating it’s use. It then examines 4 unique pharma-tech collaborations, pushing the boundaries of what was previously thought possible. With expert insights from:   Robert Califf, Former Commissioner, FDA ·       Peter Speyer, Global Head of Real World Evidence Solutions, Novartis ·       Brian Otis, CTO, Verily ·       Ajay Royyuru, Fellow and Director of Healthcare and Life Sciences, IBM ·       Thy Do, Head of Data Generation, Oncology and IBD, Takeda Follow this link to download your copy: https://goo.gl/wrmFFG

For years, discussions in pharma have centered on why it is necessary to gain patient insights for their work. Now, as this mentality gains momentum, the question has now moved on from ‘Why are we doing it?’  to ’How do we do it?’   In this webinar, eyeforpharma will tackle the most effective ways of operationalising patient-first models so that they deliver both for you, and for your ultimate customer: https://goo.gl/r56SYf   On Thursday June 29th, Guy Yeoman, VP Patient Centricity at AstraZeneca and Ruth Wilson, Head of Patient Advocacy at Teva will discuss how to:   ·       Avoid duplication and improve communication with centralized co-ordination of patient-centric efforts ·       Ensure organizational transparency and rapid access for all functional areas via a portal with tools and resources ·       Instil an enterprise-wide engagement process to help teams know how and when to engage with patients   Make sure you tune in – sign up for free here: https://goo.gl/r56SYf   Don’t worry if you can’t listen live; sign up anyway and you’ll be sent the recording.